StradBio, Inc.
- Biotech or pharma, therapeutic R&D
StradBio is an immunotherapy company using technology developed at David Baker's Institute for Protein Design and Neoleukin Therapeutics to deliver potent immune agonists to specific immune cells with the widest therapeutic index possible. DaiadTM Technology creates a logic gate so that immune activation only occurs when targeted peptides are co-localized on the surface of lymphocytes. Because the payloads are inactive in circulation, toxicities related to cytokine release syndrome can be avoided. This platform can be used to target a single antigen or two distinct antigens to maximize specificity. Our data demonstrates that targeted cells are activated at a 4-log lower concentration than target-negative cells. The Daiad technology can be applied broadly to multiple cytokine mimetics as payloads and to multiple cellular targets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}